Clinical interaction between dexamethasone and aprepitant in chemotherapy for lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Hematology"
DOI: 10.1007/s00277-022-04832-9
Abstract: Aprepitant (Apr) is an effective antiemetic agent for chemotherapy-induced nausea and vomiting (CINV). Current CINV guidelines recommend the antiemetic combination of a 5-HT3 receptor antagonist, Apr, and dexamethasone (Dex) for highly emetogenic chemotherapies. Apr inhibits… read more here.
Keywords: chemotherapy; clinical interaction; apr; interaction dexamethasone ... See more keywords